ChemoMetec ASOCSE:CHEMM +0.76%99 EBITDA Margin % is 55.47% as of Dec. 2025, which is 22% above its 10-year median of 45.31. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr523.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, ChemoMetec AS ranks better than 98.41% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ChemoMetec AS's EBITDA for the
six
months ended in Dec. 2025 was kr138.1 Mil. ChemoMetec AS's Revenue for the
six
months ended in Dec. 2025 was kr249.0 Mil. Therefore, ChemoMetec AS's EBITDA margin for the quarter that ended in Dec. 2025 was 55.47%.
ChemoMetec AS (OCSE:CHEMM) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ChemoMetec AS EBITDA Margin % Related Terms
ChemoMetec AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:CHEMM vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, ChemoMetec AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoMetec AS (OCSE:CHEMM) has a EBITDA Margin % of 55.47% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ChemoMetec AS and its competitors. This is 22% above median its historical median of 45.31. Over the past decade, ChemoMetec AS's EBITDA Margin % has ranged from 17.04 to 56.67. According to the industry distribution chart, ChemoMetec AS ranks #13 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 1.6%.
Is ChemoMetec AS's EBITDA Margin % too high?
ChemoMetec AS's current EBITDA Margin % of 55.47% is 22% above median its 10-year median of 45.31. Over the past 10 years, this metric has ranged from a low of 17.04 to a high of 56.67. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. ChemoMetec AS's value of 55.47% is 642.1% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #13 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #13 out of 816 companies for EBITDA Margin %. This places ChemoMetec AS in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. ChemoMetec AS's value of 55.47% is 642.1% above this benchmark. Historically, ChemoMetec AS's own EBITDA Margin % has ranged from 17.04 to 56.67 over the past decade. While the company's 10-year median is 45.31 vs. the industry median of 7.48, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current EBITDA Margin % of 55.47% is 642.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current EBITDA Margin % is 55.47%, which is 22% above median its own 10-year median of 45.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr523.33, compared to a current price of kr369.20 — trading 29.5% below its estimated fair value. The current EBITDA Margin % is 55.47%, which is 22% above median its 10-year median of 45.31 and 642.1% above the Medical Devices & Instruments industry median of 7.48. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current EBITDA Margin % is 55.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr369.20 is trading 29.5% below its estimated GF Value™ of kr523.33.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
EBITDA Margin %: 55.47% (22% above median its 10-year median of 45.31)
GF Value™: kr523.33 vs. price of kr369.20 (29.5% below fair value)
Industry Position: 642.1% above the Medical Devices & Instruments median (#13 of 816)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score
Get the complete analysis for OCSE:CHEMM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
